Reckitt Benckiser's Clearasil Ultra Rapid Action Treatment Cream is said to deliver visible results in just four hours.
It uses new technology, Acceladerm, to accelerate the delivery of maxiumum strength medication deep into the pore to reduce redness and spot size.
The product is salicylic acid based but is said to be unlike other AHA medicated skin care products because it contains polyhydroxy acids (PHAs), said to ensure superior product performance and improved tolerability. Its moisturising action is also said to prevent the drying and skin irritation that can be caused by some spot treatment products while antioxidants help prevent damage from UV radiation and pollution.
The launch will be supported by a TV campaign as part of a wider £3m Clearasil may cause confidence media campaign introduced in 2008 and continuing throughout 2009.